"Research and development of a brother" name is not false! 49 class 1 new drugs bright eyes, 12 first imitation winning tickets in hand, attack slow-disease drugs, high-end preparations

Recently, Hengrui Pharmaceuticals issued a series of announcements, a number of innovative drugs (including new adaptive disorders) were approved clinically, SHR-1701 paid license to East Asian companies.
the first three quarters of 2020, the company's research and development costs of 3.344 billion yuan, in the number of innovative drugs in the number of leading domestic pharmaceutical companies, "research and development of a brother" title is not false.
The company currently has 49 new drugs of class 1 and 16 new drugs of class 2 in research, focusing on anti-tumor, type 2 diabetes, pain relief and other therapeutic areas;
the first nine months of research and development investment of more than 3 billion yuan, a class of new drugs, the first imitation to Come on October 20, Hengrui Pharmaceuticals released a three-quarter report, the first three quarters of 2020 the company achieved operating income of 19.413 billion yuan, up 14.57 percent year-on-year;
Affected by the outbreak, hospital outpatient volume, surgery volume decreased, Hengrui pharmaceutical performance is still stable, presumably mainly Karelli pearl monoanti, pyridoxine, 19K and other anti-tumor innovative drugs (partial just need attributes) sales pull.
Figure: Hengrui Pharmaceutical Research and Development Expenses for the Same Period 2017-2020 (UNIT: 100 million yuan) Source: Listed companies announced that in the first three quarters of 2020, Hengrui Pharmaceutical Research and Development Expenses were 3.344 billion yuan, up 15.34% YoY, a slowdown;
currently has more than 3,400 research and development team, including more than 2000 Ph.D.s, master's degrees and more than 200 returning people, in the United States, Europe, Japan and China have many research and development centers or branches.
table 1:2020 to date Hengrui Pharma approved for listing of varieties Note: research and development costs as of the current latest announcement date source: listed companies announced this year, Hengrui Pharmaceutical new approved varieties, PD-1 Karelli Zhu single anti-new 3 adaptive disorders, Mi intranet data show that the product in 2020H1 China's public medical institutions terminal sales More than 1 billion yuan is forecast for the full year in the domestic market (China's public medical institutions and China's urban retail pharmacy terminal retail price) sales will exceed 4 billion yuan;
2020 Q4 will carry out innovative drug health insurance negotiations, Karelli zhu single resistance, Rema Lun if successfully integrated into health insurance, will further achieve the release.
four newly classified generics were approved for production, namely, praxso hydrochloric acid, proxatean ammonia chloride tablets (I.), gifitini tablets, and Glon bromide injections.
four varieties of approved enterprises are not many, the competitive pattern is good, of which the Glon ammonium bromide injection is the first imitation of the dosage form.
49 new class 1 drugs bright eyes, 4 have been declared listed as the leading pharmaceutical stocks, facing domestic policy challenges, Hengrui Pharmaceuticals has suspended a number of generic drug projects, in anti-tumor drugs, surgical anesthetics, special infusions, shadow agents, cardiovascular drugs and other areas of innovative drug research and development will be the company's future development focus.
in the research and development of innovative drugs, Hengrui pharmaceutical horizontal, vertical two-way force, while developing new varieties, while opening up new adaptive varieties listed.
Up to now, Hengrui Pharma has 5 new class 1 drugs approved for market, of which Karelli Pearl monoanti has been approved for listing, advanced nasopharyngeal cancer adaptation has been declared on the market, more than 10 joint drug treatment programs / new adhesives are carrying out Phase III clinical; 2 adaptations were approved for listing, general anaesthetic, bronchoscopy sedative 2 major adaptors are carrying out Phase III clinical;
49 new class 1 drugs in research (excluding new drugs listed to develop new adaptations), mainly concentrated in anti-tumor, type 2 diabetes, postoperative pain and other therapeutic areas, of which 4 new class 1 drugs have been declared on the market (the highest research and development progress, the same between), 6 new drugs have entered Phase III clinical.
Table 2: Hengrui Pharma in the study of 1 new drugs note: excluding the declaration of clinical and preclinical research of new drugs, the same source: MiNet China Drug Clinical Trials PublicIty Library anti-tumor is the main area of Hengrui Pharmaceutical, accounting for nearly half of the research of 1 new drugs.
fluorine palladium capsule (PARP inhibitor) has been declared on the market and is expected to be approved for sale by the end of 2020, becoming the first domestic PARP inhibitor in China; (CDK4/6 selective inhibitors), SHR3680 tablets (androgen-infused antagonists), SHR-1316 injections (PD-L1 monoantigen) are being carried out phase III clinical, research and development progress ahead of other domestic enterprises in research.
In the field of digestive system and metabolism, proline hengglie tablets (SGLT-2 inhibitors), phosphate reglitin tablets (DPP4 inhibitors) have been declared on the market, Noli glycoside injections (GLP-1 permeable astigtors) are being carried out phase II clinical, long-acting insulin INS068 injection completed phase I clinical.
In the field of diabetes is about to enter the harvest period, is expected to become the company's next stage of performance growth momentum.
In the field of cardiovascular system, injection SHR-1209 (PCSK9 monoantigen) is in Phase II clinical, for hypercholesterolemia, etc., the same target in the research of domestic enterprises also have Xinlitai, Xinda, Junshi, etc. ;
In the field of blood and hematologic systems, two major adaptive disorders, TPO-R astrations, have been declared on the market, making hyperplupa ethanolamine more efficient and less toxic than Eltrombopag.
in the field of muscle-bone systems, SHR4640 tablets (URAT1 selective inhibitors) and SHR0302 tablets (JAK1 kinase selective inhibitors) are the fastest progressing and are currently undergoing Phase III clinical work.
SHR4640 tablets for primary gout with high uric acidemia, is expected to become the first domestic class 1 new drug to treat gout;
In the field of nervous system, two new Class 1 drugs for postoperative pain, SHR0410 injections (selective CAPPA opioid-subject agitations), SHR8554 injections (MOR biased agitates), are in Phase II clinical practice, and M6G injections (opioid analgesics) are in Phase I clinical practice.
16 2 new drugs in research, offensive inhalants, lipids and other high-end preparations Hengrui pharmaceutical in improved new drugs, bio-similar drugs have also been laid out, there are currently 16 2 new drugs in research (excluding new drugs on the market to develop new adaptations), including dosage form improvement (inhalants, slow release agents, lipids, etc.), compound preparations, beval beads monobial similar drugs have been declared on the market.
Table 3: Hengrui Pharmaceuticals in the study of 2 new drug sources: Minet China Drug Clinical Trials Public Gallery 2 biosimiling drugs are Roche's star drug.
Beval pearl single anti-injection has been declared on the market, the original research products in 2019 global sales of more than 7 billion U.S. dollars, the current domestic has been approved two bio-similar drugs, spent qilu, Xinda;
high-end preparations such as offensive inhalants and lipids.
hydrochloric acid right metomide nasal spray is in Phase III clinical, currently only hydrochloric acid right metomide injection is on sale in China, in 2019 in China's public medical institutions terminal sales of more than 3 billion yuan, Hengrui is expected to win the first nasal spray type;
conclusion, although Hengrui Pharmaceuticals suspended some generic drug projects, focusing on innovative drug research and development, but imitating high-margin products that have not yet been imitated is also the company's development strategy.
a cheap and good market for generics, for pharmaceutical companies, first generics not only ensure profit margins, but also improve the team's technical level to reduce research and development risk.
meters intranet data show that at present, Hengrui Pharmaceuticals in the trial of the new classification of generic drugs produced 27, of which 15 in the domestic market blank or has not yet been approved the first imitation (including dosage form first imitation), 12 by Hengrui Pharmaceutical first or exclusive to the new classification of production.